{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:06:09Z","timestamp":1783476369432,"version":"3.55.0"},"reference-count":26,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Abstract is missing (Short communication)<\/jats:p>","DOI":"10.2340\/actadv.v102.2036","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T07:27:33Z","timestamp":1652772453000},"page":"adv00736","source":"Crossref","is-referenced-by-count":12,"title":["Tofacitinib for Treatment of Alopecia Areata: Real-world Evidence and Factors Associated with Therapeutic Response"],"prefix":"10.2340","volume":"102","author":[{"given":"Manuel","family":"Sanchez-Diaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Diaz-Calvillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Angel","family":"Rodriguez-Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Tercedor-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Rosa","family":"Cantudo-Cuenca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Molina-Leyva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Arias-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"19472","doi-asserted-by":"crossref","unstructured":"Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 2018; 78: 1-12.","DOI":"10.1016\/j.jaad.2017.04.1141"},{"key":"19473","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2017.04.1141","DOI":"10.1016\/j.jaad.2017.04.1141"},{"key":"19474","doi-asserted-by":"crossref","unstructured":"Hordinsky M, Donati A. Alopecia areata: an evidence-based treatment update. Am J Clin Dermatol 2014; 15: 231-246.","DOI":"10.1007\/s40257-014-0086-4"},{"key":"19475","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40257-014-0086-4","DOI":"10.1007\/s40257-014-0086-4"},{"key":"19476","doi-asserted-by":"crossref","unstructured":"Lalosevic J, Gajic-Veljic M, Bonaci-Nikolic B, Stojkovic Lalosevic M, Nikolic M. Combined intravenous pulse and topical corticosteroid therapy for severe alopecia areata in children: comparison of two regimens. Dermatol Ther 2019; 32: e13092.","DOI":"10.1111\/dth.13092"},{"key":"19477","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.13092","DOI":"10.1111\/dth.13092"},{"key":"19478","doi-asserted-by":"crossref","unstructured":"Phan K, Ramachandran V, Sebaratnam DF. Methotrexate for alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol 2019; 80: 120-127.e2.","DOI":"10.1016\/j.jaad.2018.06.064"},{"key":"19479","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2018.06.064","DOI":"10.1016\/j.jaad.2018.06.064"},{"key":"19480","doi-asserted-by":"crossref","unstructured":"Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2019; 33: 850-856.","DOI":"10.1111\/jdv.15489"},{"key":"19481","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15489","DOI":"10.1111\/jdv.15489"},{"key":"19482","doi-asserted-by":"crossref","unstructured":"Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs 2017; 77: 1987-2001.","DOI":"10.1007\/s40265-017-0835-9"},{"key":"19483","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40265-017-0835-9","DOI":"10.1007\/s40265-017-0835-9"},{"key":"19484","doi-asserted-by":"crossref","unstructured":"Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI insight 2016; 1: e89776.","DOI":"10.1172\/jci.insight.89776"},{"key":"19485","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1172\/jci.insight.89776","DOI":"10.1172\/jci.insight.89776"},{"key":"19486","doi-asserted-by":"crossref","unstructured":"Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 2017; 76: 22-28.","DOI":"10.1016\/j.jaad.2016.09.007"},{"key":"19487","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2016.09.007","DOI":"10.1016\/j.jaad.2016.09.007"},{"key":"19488","doi-asserted-by":"crossref","unstructured":"Yu D-A, Kim YE, Kwon O, Park H. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: a systematic review and meta-analysis. Indian J Dermatol Venereol Leprol 2021; 87: 621-627.","DOI":"10.25259\/IJDVL_975_19"},{"key":"19489","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.25259\/IJDVL_975_19","DOI":"10.25259\/IJDVL_975_19"},{"key":"19490","doi-asserted-by":"crossref","unstructured":"Olsen EA, Canfield D. SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss. J Am Acad Dermatol 2016; 75: 1268-1270.","DOI":"10.1016\/j.jaad.2016.08.042"},{"key":"19491","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2016.08.042","DOI":"10.1016\/j.jaad.2016.08.042"},{"key":"19492","doi-asserted-by":"crossref","unstructured":"Liu LY, King BA. Tofacitinib for the treatment of severe alopecia areata in adults and adolescents. J Investig Dermatology Symp Proc 2018; 19: 18-20.","DOI":"10.1016\/j.jisp.2017.10.003"},{"key":"19493","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jisp.2017.10.003","DOI":"10.1016\/j.jisp.2017.10.003"},{"key":"19494","doi-asserted-by":"crossref","unstructured":"Wollenhaupt J, Lee E-B, Curtis JR, Silverfield J, Terry K, Soma K, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 2019; 21: 89.","DOI":"10.1186\/s13075-019-1866-2"},{"key":"19495","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s13075-019-1866-2","DOI":"10.1186\/s13075-019-1866-2"},{"key":"19496","doi-asserted-by":"crossref","unstructured":"Kurosawa M, Nakagawa S, Mizuashi M, Sasaki Y, Kawamura M, Saito M, et al. A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata. Dermatology 2006; 212: 361-265.","DOI":"10.1159\/000092287"},{"key":"19497","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000092287","DOI":"10.1159\/000092287"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/2036\/5404","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/2036\/5405","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/2036\/5404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T17:18:25Z","timestamp":1655918305000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/2036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":26,"URL":"https:\/\/doi.org\/10.2340\/actadv.v102.2036","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,15]]}}}